Join the club for FREE to access the whole archive and other member benefits.

Catherine Stehman-Breen

Chief Executive Officer at Chroma Medicine

Catherine is Chief Executive Officer at Chroma Medicine and an Advisor at Atlas Venture. She also serves as an Independent Board member at Generation Bio, Tenaya Therapeutics and Dyne Therapeutics, Inc. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics where she led discovery efforts for their engineered cell and gene therapies. Prior to Obsidian Therapeutics, Catherine was an Entrepreneur in Residence at Atlas Venture and Chief Medical Officer at Sarepta Therapeutics.

In addition, Catherine held various leadership roles at Regeneron and Amgen. Catherine received her M.D. from the University of Chicago and trained as a nephrologist and earned her M.S. in epidemiology at University of Washington.

Highly experienced biopharmaceutical executive and physician-scientist with 15+ years of industry experience. Significant success in building and leading high-performing teams at both large and small companies.


Visit website: https://chromamedicine.com/people/catherine-stehman-breen/

 catherinestehmanbreen

See also: Company Chroma Medicine - Epigenetic editing company, therapy based on epigenetics

Details last updated 05-Mar-2023

Catherine Stehman-Breen News

Chroma secures new investment of 135M for Series B in genetic medicines

Chroma secures new investment of 135M for Series B in genetic medicines

Biospace - 01-Mar-2023

Epigenetic medicine approach avoids the pitfalls of traditional CRISPR method of gene editing